GW&K Investment Management LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 5.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 163,875 shares of the company’s stock after selling 8,821 shares during the quarter. Medpace makes up 0.9% of GW&K Investment Management LLC’s investment portfolio, making the stock its 14th largest holding. GW&K Investment Management LLC’s holdings in Medpace were worth $102,290,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Novem Group boosted its holdings in shares of Medpace by 1.0% in the 3rd quarter. Novem Group now owns 2,127 shares of the company’s stock worth $1,328,000 after buying an additional 22 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Medpace by 3.2% in the third quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company’s stock worth $489,000 after buying an additional 24 shares in the last quarter. Motley Fool Asset Management LLC boosted its position in shares of Medpace by 3.3% in the third quarter. Motley Fool Asset Management LLC now owns 819 shares of the company’s stock valued at $511,000 after acquiring an additional 26 shares during the period. Balefire LLC boosted its position in shares of Medpace by 7.0% in the third quarter. Balefire LLC now owns 443 shares of the company’s stock valued at $277,000 after acquiring an additional 29 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Medpace by 3.9% in the third quarter. Global Retirement Partners LLC now owns 778 shares of the company’s stock valued at $486,000 after acquiring an additional 29 shares during the period. 77.98% of the stock is currently owned by institutional investors.
Medpace Stock Down 2.0%
Shares of Medpace stock opened at $633.98 on Friday. The company’s fifty day simple moving average is $634.13 and its two-hundred day simple moving average is $534.89. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $693.97. The firm has a market cap of $17.73 billion, a PE ratio of 35.14, a price-to-earnings-growth ratio of 2.51 and a beta of 1.12.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating the consensus estimate of $4.44 by $0.40. The firm had revenue of $716.00 million during the quarter, compared to the consensus estimate of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.86 earnings per share. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 18.06 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Medpace news, VP Susan Burwig sold 16,060 shares of the company’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $677.00, for a total value of $10,872,620.00. Following the completion of the transaction, the vice president directly owned 57,624 shares in the company, valued at approximately $39,011,448. This represents a 21.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August Troendle sold 49,018 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the sale, the chief executive officer owned 433,372 shares of the company’s stock, valued at $272,205,286.92. This trade represents a 10.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 234,078 shares of company stock worth $147,170,305. Insiders own 20.50% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the stock. Robert W. Baird set a $699.00 price target on shares of Medpace in a research report on Friday, October 23rd. UBS Group lifted their price target on shares of Medpace from $673.00 to $700.00 and gave the stock a “neutral” rating in a research note on Friday, October 23rd. Truist Financial upped their price target on shares of Medpace from $609.00 to $633.00 and gave the company a “hold” rating in a research report on Friday, October 23rd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Finally, Deutsche Bank reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $649.27.
View Our Latest Analysis on Medpace
Medpace Profile
Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.
See Also
- Five stocks we like better than Medpace
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
